Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

VTE prophylaxis unaddressed in acutely ill patients

Amin A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 51.

Key clinical point: There is a significant unmet medical need for VTE prophylaxis in the continuum of care of patients hospitalized for acute medical illnesses.

Major finding: Of the overall study population, only 7% received both inpatient and outpatient VTE prophylaxis.

Study details: An analysis of national data from 17,895 acutely ill hospitalized patients.

Disclosures: The study was funded by Portola Pharmaceuticals. The presenter reported having no financial conflicts.

Source: Amin A et al. THSNA 2018, Poster 51.

Read the article.

Citation:

Amin A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 51.

This Week's Must Reads

Observational study shows hydroxyurea well tolerated in sickle cell disease, Dauvergne B et al. FSCDR 2018, presentation JSCDH-D-18-00052

Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.

Oral administration of arsenic + ATRA effective for APML, Zhu HH et al. Lancet Oncol. 2018;19:871-9.

Must Reads in Thrombosis

Large cohort study demonstrates DOAC safety vs. warfarin , Vinogradova Y et al. BMJ 2018;362:k2505.

Poor adherence to DOAC therapy requires attention, Lakkireddy D et al. Heart Rhythm 2018, Abstract B-LBCT02-03.

Sepsis-related coagulopathy and in-hospital death risk, Lyons PG et al. Crit Care Med. 2018 May;46(5):73642.

New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.

Increase kidney function monitoring if INR exceeds 4.0, Traquair H et al. biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 79.